Stevanato Group to divest California engineering plants
Stevanato Group has announced the divestment of its California plants as it reviews the role of its engineering division in the portfolio. The Italian maker of pharmaceutical containment and drug-delivery systems disclosed the move with third-quarter 2026 results, in which group revenue rose 8% to EUR 326.1m while engineering revenue fell 12%.
Why this mattersSelling the California plants would shrink Stevanato's exposure to an engineering division whose revenue fell 12% in a quarter when group revenue rose 8%.
- Stevanato has announced the divestment of its California plants amid a review of the engineering division's role
- Engineering revenue fell 12% in Q3 2026
- Biopharmaceutical and diagnostic solutions revenue rose 10% to EUR 294m, 11% organically
- Group Q3 2026 revenue rose 8% to EUR 326.1m; adjusted EBITDA rose 14% to EUR 88.8m, a 27.2% margin
- Q3 net profit rose 16% to EUR 41.8m